News
FDA Suspends U.S. License of Chikungunya Vaccine
By Stephanie Brown HealthDay ReporterMONDAY, Aug. 25, 2025 (HealthDay News) -- The U.S. Food and Drug Administration is suspending the biologics license for the live-attenuated chikungunya vaccine, Ixchiq, in the United States. The move comes after reports of serious side effects in older adults similar to the symptoms of chikungunya virus.
FDA suspends license for chikungunya vaccine Ixchiq over serious safety concerns
The US Food and Drug Administration (FDA) announced late last week that it has suspended the license for French drugmaker Valneva's chikungunya vaccine, saying that continued administration of the vaccine to the public would pose a danger to health.
A Food and Drug Administration official who stepped down less than two weeks ago is getting his job back as the agency’s top ...
The U.S. Food and Drug Administration recently approved FluMist, a flu vaccine that can be ordered online and used at home.
The Food and Drug Administration could pull Pfizer's coronavirus vaccine emergency authorization for children under age 5.
The government’s top vaccine official working under Health Secretary Robert F. Kennedy Jr. recently restricted the approval of two COVID-19 vaccines, disregarding recommendations from government ...
As a summer COVID-19 surge hits Michigan, unanswered questions abound about eligibility, insurance coverage and when new ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback